A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

Thyroid Eye Disease Clinical Trial

Official title:

A Phase 3, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Teprotumumab in Participants With Moderate-to-Severe Active Thyroid Eye Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06248619
• Other study ID #: HZNP-TEP-305
• Status: Recruiting
• Phase: Phase 3
• Start date: June 21, 2024
• Est. completion date: March 1, 2026

Study information

• Verified date: June 2024
• Source: Amgen
• Contact: Amgen Call Center
• Phone: 866-572-6436
• Email: medinfo[@]amgen.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period.

Description:

The main objective of the study is to evaluate the effect of teprotumumab subcutaneous administration versus placebo on the proptosis responder rate (ie, the percentage of participants with a ≥ 2-mm reduction from Baseline in the study eye without deterioration [≥ 2-mm increase] of proptosis in the fellow eye) at Week 24.

Acquired from Horizon in 2024.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: March 1, 2026
• Est. primary completion date: September 15, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Participant must provide written informed consent.

2. Participant can be male or female and must be between the ages of 18 and 80 years, inclusive, at Screening.

3. Participant must have a clinical diagnosis of Graves' disease associated with active TED with a CAS = 3 (on the 7-item scale) for the most severely affected eye at Screening and Baseline.

4. Participant must have moderate-to-severe active TED (not sight-threatening but has an appreciable impact on daily life), usually associated with 1 or more of the following: lid retraction = 2 mm, moderate or severe soft tissue involvement and/or inconstant or constant diplopia. (Note: Participants with no diplopia at Baseline will be limited to approximately 25% of the total number enrolled.)

5. Participant has proptosis = 3 mm from Baseline (prior to diagnosis of TED), as estimated by treating physician, and/or proptosis = 3 mm above normal for race and gender.

6. Participant had onset of active TED symptoms (as determined by participant records) within 15 months prior to Baseline.

7. Participants must be euthyroid with the baseline disease under control or have mild hypoor hyperthyroidism (defined as free thyroxine [FT4] and free triiodothyronine [FT3] levels < 50% above or below the normal limits) at Screening. Every effort should be made to correct the mild hypo- or hyperthyroidism promptly and to maintain the euthyroid state for the full duration of the trial.

8. Participant does not require immediate surgical ophthalmological intervention and is not planning corrective surgery/irradiation during the trial.

9. Women of childbearing potential must have a negative serum pregnancy test at Screening and negative urine pregnancy tests at all protocol-specified time points (ie, prior to each dose and throughout participation in the trial).

10. Participant is willing and able to comply with the protocol requirements for the duration of the trial.

Exclusion Criteria:

1. Participant has decreased best-corrected visual acuity due to optic neuropathy, defined by a decrease in vision of 2 lines on the Snellen chart (or equivalent), new visual field defect or color defect secondary to optic nerve involvement within the last 6 months.

2. Participant has corneal decompensation unresponsive to medical management.

3. Participant has a decrease in CAS of = 2 points between Screening and Baseline.

4. Participant has a decrease in proptosis of = 2 mm between Screening and Baseline.

5. Participant had prior orbital irradiation, orbital decompression or strabismus surgery (excluding childhood strabismus surgeries unrelated to TED/Graves' disease).

6. Participant is planning to have eyelid surgery during the trial.

7. Participant received periocular botulinum toxin injection within 12 months prior to Screening.

8. Participant has any systemic use of a steroid (IV or oral) or steroid eye drops for the treatment of TED or other conditions within 3 weeks prior to Screening. Exceptions include local administration (excluding periocular), eg, topical, intra-articular, and inhaled steroids, as well as steroids used to treat infusion reactions.

Related Conditions & MeSH terms

• Eye Diseases
• Graves Ophthalmopathy
• Thyroid Diseases
• Thyroid Eye Disease

Intervention

Biological:
• Teprotumumab
SC injection

Other:
• Placebo
SC injection

Locations

Country	Name	City	State
United States	W Kellogg Eye Center	Ann Arbor	Michigan
United States	University of Washington Eye Institute	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Amgen

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proptosis responder rate (percentage of participants with a = 2-mm reduction from baseline in proptosis in the study eye without deterioration [= 2-mm increase] of proptosis in the fellow eye).		Week 24
Secondary	Mean change from Baseline in proptosis measurement in the study eye		Week 24
Secondary	Overall responder rate (percentage of participants with = 2-point reduction in CAS AND = 2-mm reduction in proptosis from Baseline, provided there is no corresponding deterioration [= 2-point/mm increase] in CAS or proptosis in the fellow eye)		Week 24
Secondary	Percentage of participants with a CAS value of 0 or 1		Week 24
Secondary	Change from Baseline in diplopia as ordinal response categories		Week 24
Secondary	Diplopia responder rate, defined as the percentage of participants with Baseline binocular diplopia > 0 who have a reduction of = 1 grade		Week 24
Secondary	Complete diplopia responder rate, defined as the percentage of participants with a Baseline binocular diplopia score > 0 and a score of 0		Week 24
Secondary	Mean change from Baseline in the GO-QoL questionnaire overall score		Week 24

External Links

•   AmgenTrials clinical trials website